IC
AVTX icon

Ikarian Capital’s Avalo Therapeutics AVTX Stock Holding History

Ikarian Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-401,500
Closed -$5.99M – 158
2026
Q1 		$5.99M Buy
401,500
+343,400
+591% +$5.37M 0.49% 53
2025
Q4 		$1.06M Buy
+58,100
New +$981K 0.08% 126

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ikarian Capital's AVTX Position: Q2 2026 in Review

Ikarian Capital opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 90,183 shares worth $1.67M. The stake represents 0.18% of the portfolio and ranks #94 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in AVTX as recently as Q4 2025.

Ikarian Capital first reported a position in AVTX in Q4 2019 and has held it in 19 quarters since. The position peaked at $9.22M in Q3 2024. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Ikarian Capital held 90,183 shares of Avalo Therapeutics worth $1.67M as of Q2 2026.
  • Avalo Therapeutics was a new Ikarian Capital position in Q2 2026.
  • Avalo Therapeutics made up 0.18% of Ikarian Capital's portfolio in Q2 2026, its #94 holding.
  • Ikarian Capital first reported a position in Avalo Therapeutics in Q4 2019 and has held it in 19 quarters since.
  • Ikarian Capital's Avalo Therapeutics position peaked at $9.22M in Q3 2024.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.